By Connor Hart

AngioDynamics raised its full-year outlook after posting higher sales and a narrower loss in its fiscal first quarter, which Chief Executive Jim Clemmer attributed to continuing momentum in the business.

The medical-technology company on Thursday said it now expects to log an adjusted loss of 23 cents a share to 33 cents a share in its fiscal 2026, compared with a prior view for a loss of 25 cents a share to 35 cents a share.

It also lifted its sales outlook to $308 million to $313 million, from $305 million to $310 million. The company noted its outlooks include an up-to $6 million impact from tariffs.

Analysts polled by FactSet expected an adjusted loss of 31 cents a share on sales of $306.7 million.

The outlooks came as AngioDynamics posted a loss of $10.9 million, or 26 cents a share, for its quarter ended Aug. 31. That compares with a loss of $12.8 million, or 31 cents a share, in last year's comparable quarter.

On an adjusted basis--which strips out exceptional and other one-off items--the company notched a loss of 10 cents a share. Analysts had forecast an adjusted loss of 12 cents a share.

Quarterly sales increased 12% to $75.7 million, topping Wall Street models for $72.3 million. Sales of medical devices accounted for just over half of sales, with sales of medical technologies accounting for the rest.

Shares rose 5.5% to $11.68 in premarket trading. Through Wednesday's close, the stock is up more than 20% so far this year.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

October 02, 2025 06:31 ET (10:31 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.